Changes

Jump to: navigation, search

Erdafitinib (Balversa)

599 bytes added, 14:35, 12 May 2019
added package insert & links
==General information==
Class/mechanism, from the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/erdafitinib NCI Drug Dictionary]: An orally bioavailableTyrosine kinase inhibitor of multiple receptor tyrosine kinases (RTKs), pan including fibroblast growth factor receptor receptors (FGFR) inhibitor with potential antineoplastic activity. Upon oral administrationFGFR1, FGFR2, FGFR3, FGFR4, as well as RET, CSF1R, PDGFRA, PDGFRB, FLT4, KIT, erdafitinib binds to and VEGFR2. Erdafinitinib inhibits FGFR, which may result in the inhibition of FGFR-related phosphorylation and signal transduction pathways and thus the , resulting in inhibition of tumor cell proliferation and tumor cell death in FGFR-overexpressing tumor cells.<ref name="insert">[http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/BALVERSA-pi.pdf Erdafitinib (Balversa) package insert]</ref><ref>[[Media:Erdafinitib.pdf| Erdafitinib (Balversa) package insert (locally hosted backup)]]</ref><ref>[https://www.balversa.com/ Balversa manufacturer's website]</ref>
<br>Route: PO
<br>Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert.<ref name="insert"></ref>
==Diseases for which it is used==
*[[Bladder cancer]]
 
==Patient drug information==
*[http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/BALVERSA-pi.pdf Erdafitinib (Balversa) package insert]<ref name="insert"></ref>
==History of changes in FDA indication==
*4/12/2019: [https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-metastatic-bladder-cancer Accelerated FDA approval ] for "adult patients with locally advanced or metastatic [[Bladder_cancer|urothelial carcinoma]], with that has susceptible FGFR3 or FGFR2 genetic alterations, that has and progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy."
==Also known as==
LookupUsers, editors, emailconfirmed
3,827
edits

Navigation menu